Overview
KVUE market data
Price History
KVUE price chart
Valuation & Profitability
- P/E (TTM)
- 22.24 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.76 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.45 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.4% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 10.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.02 – $21.96 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $36.9B · P/B 3.06 · P/S 2.39.
Company News
South Africa's Competition Tribunal Says Deal Between Kimberly-Clark Corporation And Kenvue Approved With ConditionsBenzinga · Aug 14, 2026, 4:35 PM
UBS Maintains Neutral on Kenvue, Lowers Price Target to $19Benzinga · Aug 11, 2026, 9:00 PM
Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong' (UPDATED)Benzinga · Aug 11, 2026, 3:01 AM
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions'Benzinga · Aug 7, 2026, 12:36 PM
Kenvue shares are trading lower after the company reported worse-than-expected Q2 financial results.Benzinga · Aug 6, 2026, 6:48 PM
8-K filing — Kenvue Inc. (KVUE)SEC EDGAR · Aug 6, 2026, 10:48 AM
Kenvue Q2 Adj. EPS $0.31 Misses $0.32 Estimate, Sales $3.955B Miss $3.966B EstimateBenzinga · Aug 6, 2026, 10:46 AM
Kenvue Increases Quarterly Dividend By 1.2% To $0.21 Per ShareBenzinga · Jul 29, 2026, 10:46 AM
Johnson & Johnson Puts 15-Year Meritless Talc Litigation To RestBenzinga · Jul 28, 2026, 2:10 PM
FDA Approves Kenvue’s TYLENOL With Naproxen, OTC Fixed-Dose Combination Of Acetaminophen And Naproxen SodiumBenzinga · Jul 24, 2026, 6:05 PM